• Ticker

    Advertisement Find a Broker - Visit the DailyFinance Broker Center
DJIA 12,454.83 -74.92 -0.60%
NASDAQ 2,837.53 -1.85 -0.07%
S&P 500 1,317.82 -2.86 -0.22%

$0.39 -$0.01 (-2.48%)

REAL-TIME: Last trade at

Rexahn Pharmaceuticals

AMEX:RNN

Jump to this page for:

Related Resources

Rexahn Pharmaceuticals: Update On Cancer Drugs

5/17/2012 by Seeking Alpha

Rexahn Pharmaceuticals Submits Archexin Phase II Protocol For Ovarian Cancer To FDA

5/9/2012 by Pharmaceutical Online

Rexahn Pharmaceuticals Submits Archexin Phase II Protocol for Ovarian Cancer to FDA

5/8/2012 by PharmiWeb.com - UK

Rexahn Pharmaceuticals submits Phase II protocol of Archexin to FDA

5/8/2012 by Theflyonthewall.com

Rexahn Pharmaceuticals Issued Japanese Patent for New Anti-cancer Compounds

4/30/2012 by PharmiWeb.com - UK

Rexahn Pharmaceuticals issued Japanese patent for new anti-cancer compunds

4/30/2012 by Theflyonthewall.com

Rexahn Pharmaceuticals Issued Japanese Patent for New Anti-cancer Compounds

4/30/2012 by Business Wire

Rexahn Pharmaceuticals Focus On Cancer May Pay Off

3/30/2012 by Seeking Alpha

Rexahn Pharmaceuticals to Present Data on Novel Anti-Cancer Small Molecule RX-3117 at AACR 103rd Annual Meeting

3/27/2012 by PharmiWeb.com - UK

Rexahn Pharmaceuticals to Present Data on Novel Anti-Cancer Small Molecule RX-3117 at AACR 103rd Annual Meeting

3/27/2012 by Business Wire

Rexahn initiates Phase I cancer trial of RX-3117

3/14/2012 by Pharmaceutical Business Review Online - UK

Rexahn Pharmaceuticals enrolls first patient in RX-3117 clinical trial

3/13/2012 by Theflyonthewall.com

Rexahn Pharmaceuticals Enrolls First Subject in Exploratory Phase I Clinical Study of RX-3117

3/13/2012 by Business Wire

Rexahn Pharmaceuticals Publishes New Preclinical Data for Quinoxalinyl-Piperazine Compounds

1/25/2012 by PharmiWeb.com - UK

Rexahn Pharmaceuticals publishes new preclinical data for Quinoxalinyl compound

1/25/2012 by Theflyonthewall.com

Rexahn Pharmaceuticals Publishes New Preclinical Data for Quinoxalinyl-Piperazine Compounds

1/25/2012 by Business Wire

Rexahn Pharma Gets Approval For First Human Trial Of RX-3117

1/18/2012 by RTTNews

Rodman & Renshaw Cuts Rexahn Pharma (RNN) to Market Perform

1/18/2012 by StreetInsider.com

Rexahn rated Market Perform from Under Review at Rodman & Renshaw

1/18/2012 by Theflyonthewall.com

Rexahn Pharmaceuticals Secures Approval in Europe to Conduct a First-in-Human Trial of RX-3117 in Solid Tumors

1/18/2012 by PharmiWeb.com - UK

Rexahn Pharmaceuticals Secures Approval in Europe to Conduct a First-in-Human Trial of RX-3117 in Solid Tumors

1/18/2012 by Business Wire

Rexahn Pharmaceuticals Provides Key Goals for 2012

1/17/2012 by PharmiWeb.com - UK

Rexahn Pharmaceuticals comments on key goals for 2012

1/17/2012 by Theflyonthewall.com

Rexahn Pharmaceuticals Provides Key Goals for 2012

1/17/2012 by Business Wire

Drug Candidates From Rexahn And Elite Pharmaceuticals Look To Pass Key Tests

11/10/2011 by Pharmaceutical Online

Drug Candidates From Rexahn and Elite Pharmaceuticals Look to Pass Key Tests

11/9/2011 by StockWatch

Drug Candidates From Rexahn and Elite Pharmaceuticals Look to Pass Key Tests

11/9/2011 by Marketwire

Rexahn Pharmaceuticals, Inc.'s Serdaxin(R) Disappoints in Phase II Trial for Major Depressive Disorder

11/4/2011 by BioSpace

Rexahn Pharmaceuticals (RNN) Offers Results from Phase II Trial of Serdaxin for Major Depressive Disorder

11/4/2011 by StreetInsider.com

Rexahn Pharmaceuticals announces Phase II Serdaxin results

11/4/2011 by Theflyonthewall.com

Rexahn Pharmaceuticals Announces Phase II Results for Serdaxin® as Treatment for Major Depressive Disorder

11/4/2011 by Business Wire

Rexahn Pharmaceuticals Granted US Patent for Novel Anti-cancer Isoquinolinamine Compounds

10/12/2011 by PharmiWeb.com - UK

Rexahn Pharmaceuticals granted U.S. patent for isoquinolinamine compounds

10/12/2011 by Theflyonthewall.com

Rexahn Pharmaceuticals Granted US Patent for Novel Anti-cancer Isoquinolinamine Compounds

10/12/2011 by Business Wire

Rexahn Pharmaceuticals Announces Publication of Study Validating Mechanism of Action of Serdaxin®

10/3/2011 by PharmiWeb.com - UK

Rexahn announces publication of study validating mechanism of action of clavulan

10/3/2011 by Theflyonthewall.com

Rexahn Pharmaceuticals Announces Publication of Study Validating Mechanism of Action of Serdaxin®

10/3/2011 by Business Wire

Rexahn Pharmaceuticals advances pancreatic cancer drug

9/28/2011 by Washington Business Journal - Washington DC

Rexahn Pharmaceuticals Completes Patient Enrollment for Archexin Phase II Clinical Trial in Metastatic Pancreatic Cancer

9/28/2011 by PharmiWeb.com - UK

Rexahn Pharmaceuticals completes enrollment for Archexin Phase II trial

9/28/2011 by Theflyonthewall.com
See More Articles...